Lirilumab combo shows early promise in SCCHN

Innate Pharma S.A. (Euronext:IPH) reported preliminary data from a Phase I/II trial of lirilumab (IPH2102) plus PD-1 inhibitor Opdivo nivolumab that suggest the

Read the full 230 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE